These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

618 related articles for article (PubMed ID: 32390826)

  • 21. Lack of additive role of ageing in nigrostriatal neurodegeneration triggered by α-synuclein overexpression.
    Bourdenx M; Dovero S; Engeln M; Bido S; Bastide MF; Dutheil N; Vollenweider I; Baud L; Piron C; Grouthier V; Boraud T; Porras G; Li Q; Baekelandt V; Scheller D; Michel A; Fernagut PO; Georges F; Courtine G; Bezard E; Dehay B
    Acta Neuropathol Commun; 2015 Jul; 3():46. PubMed ID: 26205255
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
    Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
    PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNAJB6 suppresses alpha-synuclein induced pathology in an animal model of Parkinson's disease.
    Arkan S; Ljungberg M; Kirik D; Hansen C
    Neurobiol Dis; 2021 Oct; 158():105477. PubMed ID: 34390836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson's Disease.
    Duffy MF; Collier TJ; Patterson JR; Kemp CJ; Fischer DL; Stoll AC; Sortwell CE
    Front Neurosci; 2018; 12():621. PubMed ID: 30233303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structurally distinct α-synuclein fibrils induce robust parkinsonian pathology.
    Hayakawa H; Nakatani R; Ikenaka K; Aguirre C; Choong CJ; Tsuda H; Nagano S; Koike M; Ikeuchi T; Hasegawa M; Papa SM; Nagai Y; Mochizuki H; Baba K
    Mov Disord; 2020 Feb; 35(2):256-267. PubMed ID: 31643109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review: Spreading the word: precise animal models and validated methods are vital when evaluating prion-like behaviour of alpha-synuclein.
    Rey NL; George S; Brundin P
    Neuropathol Appl Neurobiol; 2016 Feb; 42(1):51-76. PubMed ID: 26666838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Authentically phosphorylated α-synuclein at Ser129 accelerates neurodegeneration in a rat model of familial Parkinson's disease.
    Sato H; Arawaka S; Hara S; Fukushima S; Koga K; Koyama S; Kato T
    J Neurosci; 2011 Nov; 31(46):16884-94. PubMed ID: 22090514
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
    Benskey MJ; Perez RG; Manfredsson FP
    J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
    Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
    Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glutathione
    Jewett M; Dickson E; Brolin K; Negrini M; Jimenez-Ferrer I; Swanberg M
    Front Neurol; 2018; 9():222. PubMed ID: 29681884
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson's disease models.
    Arcos J; Grunenwald F; Sepulveda D; Jerez C; Urbina V; Huerta T; Troncoso-Escudero P; Tirado D; Perez A; Diaz-Espinoza R; Nova E; Kubitscheck U; Rodriguez-Gatica JE; Hetz C; Toledo J; Ahumada P; Rojas-Rivera D; Martín-Montañez E; Garcia-Fernandez M; Vidal RL
    Cell Death Discov; 2023 Dec; 9(1):438. PubMed ID: 38042807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats.
    Thomsen MB; Ferreira SA; Schacht AC; Jacobsen J; Simonsen M; Betzer C; Jensen PH; Brooks DJ; Landau AM; Romero-Ramos M
    Neurobiol Dis; 2021 Feb; 149():105229. PubMed ID: 33352233
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential of Cellular and Animal Models Based on a Prion-Like Propagation of α-Synuclein for Assessing Antiparkinson Agents.
    Sato H; Kato T; Arawaka S
    Mol Neurobiol; 2015 Aug; 52(1):226-35. PubMed ID: 25143237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro.
    Marotta NP; Ara J; Uemura N; Lougee MG; Meymand ES; Zhang B; Petersson EJ; Trojanowski JQ; Lee VM
    Acta Neuropathol Commun; 2021 Nov; 9(1):188. PubMed ID: 34819159
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progression of phosphorylated α-synuclein in Macaca fuscata.
    Kawakami I; Motoda A; Hashimoto M; Shimozawa A; Masuda-Suzukake M; Ohtani R; Takase M; Kumashiro M; Samejima K; Hasegawa M
    Brain Pathol; 2021 Sep; 31(5):e12952. PubMed ID: 33754430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. α-synuclein aggregation and its modulation.
    Ghosh D; Mehra S; Sahay S; Singh PK; Maji SK
    Int J Biol Macromol; 2017 Jul; 100():37-54. PubMed ID: 27737778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Overview on the Role of α -Synuclein in Experimental Models of Parkinson's Disease from Pathogenesis to Therapeutics.
    Javed H; Kamal MA; Ojha S
    CNS Neurol Disord Drug Targets; 2016; 15(10):1240-1252. PubMed ID: 27658511
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of α-Synuclein by Oligodendrocytes in Transgenic Mice Does Not Recapitulate the Fibrillar Aggregation Seen in Multiple System Atrophy.
    Laferrière F; He X; Zinghirino F; Doudnikoff E; Faggiani E; Meissner WG; Bezard E; De Giorgi F; Ichas F
    Cells; 2020 Oct; 9(11):. PubMed ID: 33138150
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates α-synuclein Pathology in a Mouse Model of α-Synuclein Propagation.
    Tavassoly O; Del Cid Pellitero E; Larroquette F; Cai E; Thomas RA; Soubannier V; Luo W; Durcan TM; Fon EA
    Neurotherapeutics; 2021 Apr; 18(2):979-997. PubMed ID: 33713002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exogenous α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death.
    Volpicelli-Daley LA; Luk KC; Patel TP; Tanik SA; Riddle DM; Stieber A; Meaney DF; Trojanowski JQ; Lee VM
    Neuron; 2011 Oct; 72(1):57-71. PubMed ID: 21982369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.